Physician profile
Jack Lee
NPI 1083675318
$20,644.07
in general payments reported to CMS, 2019-2025
41 companies · $4,704 in 2025
The $4,704 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,231 · 2020: $2,001 · 2021: $2,685 · 2022: $2,924 · 2023: $3,045 · 2024: $3,055 · 2025: $4,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $350 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,239.65 |
| Consulting Fee | $350.00 |
| Education | $214.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,084.87 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $3,052.46 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,785.94 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,578.83 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $1,175.44 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $1,056.16 | 2019-2024 | Yupelri |
| Genzyme Corporation | $857.71 | 2019-2025 | |
| Axsome Therapeutics, INC. | $779.21 | 2022-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $774.54 | 2019-2025 | |
| Philips North America LLC | $656.54 | 2019-2024 | (Ak6) Vest Therapy, (8874) Incourage |
| Mallinckrodt Hospital Products INC. | $515.62 | 2020-2025 | Acthar |
| Amgen INC. | $477.49 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $456.22 | 2019-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $394.08 | 2019-2021 | |
| United Therapeutics Corporation | $379.65 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $362.18 | 2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $350.47 | 2020-2025 | Aralast |
| Pfizer INC. | $330.43 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $315.19 | 2023-2025 | Lumryz |
| Viatris Specialty LLC | $208.12 | 2025 | Yupelri |
| Covis Pharma Gmbh | $194.38 | 2021-2023 | |
| Inspire Medical Systems, INC. | $191.21 | 2023-2025 | Inspire |
| Insmed, INC. | $181.60 | 2022-2025 | Arikayce, Brinsupri |
| Teva Pharmaceuticals USA, INC. | $176.64 | 2019-2023 | |
| Verona Pharma, INC. | $171.60 | 2025 | Ohtuvayre |
| E.R. Squibb & Sons, L.L.C. | $158.77 | 2021-2024 | Eliquis |
| Vifor Pharma, INC. | $148.92 | 2024-2025 | Zemaira |
| Genentech USA, INC. | $137.77 | 2019-2023 | Xolair |
| Bayer Healthcare Pharmaceuticals INC. | $129.15 | 2022-2024 | |
| Pulmonx Corporation | $121.76 | 2021-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Merck Sharp & Dohme LLC | $100.51 | 2019-2025 | Capvaxive |
| Circassia INC. | $61.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $51.44 | 2019-2022 | |
| Aerin Medical INC. | $42.40 | 2024 | |
| Shire North American Group INC | $38.67 | 2019 | |
| Baxter Healthcare | $35.84 | 2025 | Hillrom - Monarch Airway Clearance System |
| Gilead Sciences, INC. | $34.23 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $26.56 | 2019 | |
| Biocryst US Sales Co., LLC | $17.70 | 2025 | Orladeyo |
| Resmed Corp | $16.59 | 2025 | |
| Lilly USA, LLC | $16.01 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.